Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Eligible patients have prostate cancer that was treated with surgery or radiation therapy for
localized disease and there is evidence of biochemical recurrence and/or metastases on
conventional imaging.The objective of this study is to assess the performance in detection of
prostate cancer of a new positron emission tomography (PET) radiotracer for prostate cancer
([18F]-DCFPyl) combined with magnetic resonance imaging (MRI). Results of tracer uptake and
MRI image features as whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and
together, will be correlated and compared to detection of lesions on conventional imaging
modalities. Additionally, if the patient undergoes a biopsy as standard of care, image
features will correlate directly with histopathological findings.Validation of this
radiotracer can potentially lead to its use as a standard of care for future imaging and
improve diagnosis and treatment guidance.This drug is not approved by the Food and Drug
Administration (FDA) and is therefore considered experimental.There will be 20 subjects
enrolled in this study; all of these patients will be enrolled at Stony Brook University
Medical Center.